Archives: Speakers

Dr. Brannan is the former CMO at Karuna Therapeutics and a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience.  Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various senior roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. His experience includes drug development, registration, medical affairs, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, migraine, cognition, and Alzheimer’s and Parkinson’s diseases. Dr. Brannan is a member of several scientific societies and groups, including ACNP, ISCTM (Member of both the Scientific and Executive Committees), ISCDD, AARR, IOM Neuroforum, and CNS Summit (founding member). Prior to joining the Pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio (UTHSCSA) where he specialized in seeing Mood and Anxiety disorder patients, ran a clinical research unit, and did neuroimaging research at the Research Imaging Center.  Dr. Brannan trained in psychiatry at UTHSCSA and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School). He has over 50 publications and routinely gives invited talks and presentations at industry conferences.

Roger is an Associate Director in Deloitte’s Markets Assurance group, with a particular focus on algorithms and regulatory change. He has a deep understanding of algorithms, gained through over 20 years of experience in the UK and in Europe, and has a thorough technical knowledge of the regulatory landscape related to Artificial Intelligence. As a senior member of the Algorithm Assurance team, Roger has been a key figure in the design and development of Deloitte’s methodology for auditing AI. He has also supported numerous technology companies in their development of control frameworks for regulatory compliance as they move through this period of major change.

Is a well-recognized identity technology expert. He serves as the SVP, Head of Americas for iProov, a global provider of biometric authentication products used for online enrollment and verification. Ajay also serves as a strategic advisor for identity to leaders in e-commerce, artificial intelligence, and identity technology ranging from publicly-traded companies such as DocuSign (NASDAQ: DOCU) and PayPal (NASDAQ: PYPL), Credence ID, venture capital investors, and small to midsize disruptor companies. From 2019-2021, after his startup was acquired by Idemia (a $3B Paris-based identity technology company), he reported to the CEO and served as their SVP Corporate Strategy/Development and their GM of the Commercial Business Unit.

Miguel is responsible for the technology function in iProov, including engineering and platform and IT operations.

Prior to joining iProov, Miguel was Chief Information Officer for Operations and Economic Crime at Santander UK, where he had various engineering and transformation roles overseeing multi-disciplinary teams around the world.

He began his career with Accenture, running financial services projects in Europe and Latin America.

Lou Anne spent more than 12 years with Early Warning® (EW), a fintech company owned by seven of the largest U.S. banks, where she led the U.S. launch of the Zelle Network® payment service. She most recently served as EW’s Chief Product Officer, responsible for all identity verification services for new account openings, as well as a bank-sponsored digital identity service.

Lou Anne previously held senior leadership positions with Wells Fargo and its predecessor banks, Wachovia and First Union. She is currently a partner at Open Loop Strategies LLC and serves as a board member and strategic advisor to iProov and several notable software as a service (SaaS) companies.

My role is the global Head of Corporate Affairs for Next Generation Products at Imperial Brands. I have 12 years in the business including Group Corporate Affairs, Head of Government Affairs in UK market, Head of Policy for Fontem. Previously, I started my career in Westminster,UK with 10 years of experience across public affairs, consultancy and the civil service.

My passions are my family, politics, and the environment.

Before joining the PMO team at Broughton in 2019, Ben held a number of senior QC and supply chain positions within the Pharmaceutical industry, working on pandemic response & global vaccine campaign launches.

• Ben has over 10 years experience in a number of key roles within FDA & MHRA regulated industries, including development and testing of pandemic vaccines and delivery systems in use globally, Manufacturing and supply chain process management, as well as quality auditing & engagement with FDA & MHRA inspectors.
• He has coordinated a significant number of regulatory submissions to both the FDA’s CBER and CTP offices, most recently developing and leading successful delivery of PMTA submissions for major clients in the next generation nicotine industry.

Ben holds a BSc (Hons) in Applied Biomedical Science and began his career in vaccine research and diagnostics, supporting vaccine development, production and rapid pandemic response as part of the quality control microbiology department. Moving into operations & supply chain, gave him the opportunity to plan, manage & deliver global vaccine campaigns.

Ben has delivered several major and complex projects for key clients, showing a keen passion for regulatory compliance & development of strategies to best place clients in a position to successfully meet the application & marketing requirements of the FDA and MHRA.

In his ability to develop excellent professional relationships, Ben has a proven track record of working alongside clients in identifying opportunities to bring new products to market & utilize efficient processes for delivery of regulatory submissions on time & in-budget.

Ben is committed to ensuring clients are able to access the very latest regulatory intelligence in consultation with Broughton to successfully bring their life-enhancing products into the commercial space.

Isra leads the Product team at Causaly, working alongside our customers and users to create product experiences that deliver value. Her experiences have focused on growth strategy, and new product and business models, having worked in strategy consulting and corporate strategy across Roland Berger, LexisNexis and the World Bank. She holds a BA in Economics from Macalester College, and an MBA from London Business School.

Yiannis is a computer scientist and has consulted with the world’s largest companies before co-founding Causaly in 2018. Yiannis holds a Bachelor and master’s in computer science, an MBA from Hong Kong University of Science and Technology and took part in Singularity University’s Future Studies program.